Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.As of 26 May 2026, Suven Pharmaceuticals share price is ₹434.90. The stock opened at ₹436.00, compared to its previous close of ₹434.85. During today's trading session, Suven Pharmaceuticals share price moved in the range of ₹431.85 to ₹444.75, with an average price of ₹438.30 for the day. Looking at its last 52-week, the stock has touched a low of ₹431.85 and a high of ₹444.75.
The market capitalization of Suven Pharmaceuticals is ₹16,634 Crs, with a P/E ratio of 106.8 and a dividend yield of 0.00%.